Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/142352
Title: Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates
Authors: Eriksson, Olof
Velikyan, Irina
Haack, Torsten
Bossart, Martin
Evers, Andreas
Laitinen, Iina
Larsen, Philip J.
Plettenburg, Oliver
Takano, Akihiro
Halldin, Christer
Antoni, Gunnar
Johansson, Lars
Pierrou, Stefan
Wagner, Michael
Keywords: Science::Medicine
Issue Date: 2019
Source: Eriksson, O., Velikyan, I., Haack, T., Bossart, M., Evers, A., Laitinen, I., . . . Wagner, M. (2019). Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates. Scientific Reports, 9(1), 14960-. doi:10.1038/s41598-019-51530-0
Journal: Scientific Reports
Abstract: The glucagon receptor (GCGR) is an emerging target in anti-diabetic therapy. Reliable biomarkers for in vivo activity on the GCGR, in the setting of dual glucagon-like peptide 1/glucagon (GLP-1/GCG) receptor agonism, are currently unavailable. Here, we investigated [68Ga]Ga-DO3A-S01-GCG as a biomarker for GCGR occupancy in liver, the tissue with highest GCGR expression, in non-human primates (NHP) by PET. [68Ga]Ga-DO3A-S01-GCG was evaluated by dynamic PET in NHPs by a dose escalation study design, where up to 67 µg/kg DO3A-S01-GCG peptide mass was co-injected. The test-retest reproducibility of [68Ga]Ga-DO3A-S01-GCG binding in liver was evaluated. Furthermore, we investigated the effect of pre-treatment with acylated glucagon agonist 1-GCG on [68Ga]Ga-DO3A-S01-GCG binding in liver. [68Ga]Ga-DO3A-S01-GCG bound to liver in vivo in a dose-dependent manner. Negligible peptide mass effect was observed for DO3A-S01-GCG doses <0.2 µg/kg. In vivo Kd for [68Ga]Ga-DO3A-S01-GCG corresponded to 0.7 µg/kg, which indicates high potency. The test-retest reproducibility for [68Ga]Ga-DO3A-S01-GCG binding in liver was 5.7 ± 7.9%. Pre-treatment with 1-GCG, an acylated glucagon agonist, resulted in a GCGR occupancy of 61.5 ± 9.1% in liver. Predicted human radiation dosimetry would allow for repeated annual [68Ga]Ga-DO3A-S01-GCG PET examinations. In summary, PET radioligand [68Ga]Ga-DO3A-S01-GCG is a quantitative biomarker of in vivo GCGR occupancy.
URI: https://hdl.handle.net/10356/142352
ISSN: 2045-2322
DOI: 10.1038/s41598-019-51530-0
Rights: © 2019 The Author(s). This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. Te images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles

SCOPUSTM   
Citations 50

7
Updated on Jan 21, 2023

Web of ScienceTM
Citations 20

7
Updated on Jan 24, 2023

Page view(s)

165
Updated on Jan 26, 2023

Download(s) 50

40
Updated on Jan 26, 2023

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.